NVAX FY 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$556M-65.2% YoY

Gross Profit

$213M38.2% margin

Operating Income

-$567M-101.8% margin

Net Income

-$545M-98.0% margin

EPS (Diluted)

$-5.41

Cash Flow

Operating Cash Flow

-$714M

Free Cash Flow

-$773M

Stock-Based Comp.

$85M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.5B

Stockholders' Equity

-$717M

Cash & Equivalents

$569M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$556M	$1.6B	-65.2%
Gross Profit	$213M	$696M	-69.5%
Operating Income	-$567M	-$645M	+12.1%
Net Income	-$545M	-$658M	+17.2%